ARTICLE | Clinical News
More telbivudine Phase III data
March 28, 2006 2:37 AM UTC
Idenix (IDIX) and Novartis (NVS; SWX:NOVN) said that telbivudine met the primary endpoint of superiority to lamivudine on therapeutic response at one year in a two-year Phase III trial to treat chroni...